Baseline demographics, risk factors, and history of coronary artery disease for all patients, showing the number and percent according to the treatment groups
| Characteristic . | Placebo (n = 353) . | Orbofiban 50/30 mg (n = 353) . | Orbofiban 50/50 mg (n = 308) . |
|---|---|---|---|
| Demographics | |||
| Age, y (± SD) | 58.8 (11.2) | 58.3 (11.0) | 57.7 (11.0) |
| Male (%) | 250 (72.5) | 275 (78.8) | 227 (75.2) |
| Smoker | |||
| Current (%) | 127 (36.0) | 143 (40.5) | 138 (44.8) |
| Former (%) | 121 (34.3) | 112 (31.7) | 84 (27.3) |
| Nonsmoker (%) | 105 (29.7) | 98 (27.8) | 86 (27.9) |
| Presentation | |||
| MI (%) | 202 (57.2) | 217 (61.5) | 184 (59.7) |
| UA (%) | 151 (42.8) | 136 (38.5) | 124 (40.3) |
| Family history CVD (%) | 177 (50.1) | 159 (45.0) | 151 (49.0) |
| Diabetes mellitus (%) | 67 (19.0) | 52 (14.7) | 56 (18.2) |
| Hypercholesterolemia (%) | 119 (33.7) | 105 (29.8) | 83 (27.1) |
| Hypertension (%) | 157 (44.5) | 144 (40.8) | 136 (44.2) |
| PlA2 carriers (%) | 97 (27.5) | 100 (28.3) | 70 (22.7) |
| Characteristic . | Placebo (n = 353) . | Orbofiban 50/30 mg (n = 353) . | Orbofiban 50/50 mg (n = 308) . |
|---|---|---|---|
| Demographics | |||
| Age, y (± SD) | 58.8 (11.2) | 58.3 (11.0) | 57.7 (11.0) |
| Male (%) | 250 (72.5) | 275 (78.8) | 227 (75.2) |
| Smoker | |||
| Current (%) | 127 (36.0) | 143 (40.5) | 138 (44.8) |
| Former (%) | 121 (34.3) | 112 (31.7) | 84 (27.3) |
| Nonsmoker (%) | 105 (29.7) | 98 (27.8) | 86 (27.9) |
| Presentation | |||
| MI (%) | 202 (57.2) | 217 (61.5) | 184 (59.7) |
| UA (%) | 151 (42.8) | 136 (38.5) | 124 (40.3) |
| Family history CVD (%) | 177 (50.1) | 159 (45.0) | 151 (49.0) |
| Diabetes mellitus (%) | 67 (19.0) | 52 (14.7) | 56 (18.2) |
| Hypercholesterolemia (%) | 119 (33.7) | 105 (29.8) | 83 (27.1) |
| Hypertension (%) | 157 (44.5) | 144 (40.8) | 136 (44.2) |
| PlA2 carriers (%) | 97 (27.5) | 100 (28.3) | 70 (22.7) |
MI indicates myocardial infarction; UA, unstable angina; CVD, cardiovascular disease.